Daria G. Ulrikh

Daria G. Ulrikh

Auto-generated profile, based on publicly available information

Daria G. Ulrikh

N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
DUD.G. Ulrikh
D.G. Ulrikh
PKP.V. Krivorotko
P.V. Krivorotko
ZBZh.V. Bryantseva
Zh.V. Bryantseva
RPR.S. Pesotskiy
R.S. Pesotskiy
YBY.I. Bondarchuk
Y.I. Bondarchuk
VSV.F. Semiglazov
V.F. Semiglazov
Background. Breast reconstruction after mastectomy must consider potential complications from surgical techniques as well as additional complications that may arise from oncologic treatment steps such as radiation or systemic therapy. But the consensus is lacking regarding the optimal reconstruction plan for patients requiring adjuvant radiation therapy. Objective. To determine the impact of risk factors on the development complications of breast reconstruction for postmastectomy radiotherapy. Material and methods. This study included patients diagnosed with breast cancer who received combination treatment from 2016 to 2021 at the N.N. Petrov National Medical Research Center of Oncology. The patients were divided into 3 groups: immediate reconstruction (158 people), immediate-delayed (210 people) and delayed (98 people). Results. Every fourth patient (24.0%, 112/466) may encounter a complication after mastectomy with reconstruction and adjuvant radiation therapy. According to the analyzed data, there was no correlation between potential risk factors depending on the general status of patients (age, obesity, diabetes mellitus, hypertension, history of smoking) and the occurrence of complications after combination treatment. Conclusion. The analysis of complications and reconstructive failures showed that immediate breast reconstruction at the N.N. Petrov National Medical Research Center of Oncology is the safest method of reconstruction in the combined treatment of breast cancer with the lowest incidence of severe complications, which plays a key role in the development of reconstructive failures. However, these surgeries are associated with a significant number of capsular contractures, which requires finding ways to minimize these risks to optimize treatment in each individual case in short and long term.

25 July 2024 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
ZBZh. V. Bryantseva
Zh. V. Bryantseva
SNS. N. Novikov
S. N. Novikov
DUD. G. Ulrikh
D. G. Ulrikh
ПКП. В. Криворотько
П. В. Криворотько
IAI. A. Akulova
I. A. Akulova
KZK. Yu. Zernov
K. Yu. Zernov
Background. One of the causes of complications in breast cancer patients after immediate breast reconstruction (IBR) is postmastectomy radiation therapy (PMRT).Aim. Retrospective analysis of the results of IBR, and evaluating the effect of PMRT on the frequency and type of complications.Materials and methods. Between 2015 and 2021, 798 patients underwent IBR with tissue expander or implant in N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia. PMRT was performed in 375 patients (group 1). The remaining 423 patients did not receive PMRT (group 2). Complications, including reconstructive failure (RF), Baker grade III/IV capsular contracture (CC), were recorded and analyzed.Results. Finally, cosmetic result analyzed in 521 patients. In 281 patients of PMRT group (group 1) IBR with expander or implant were performed in 144 and 137 cases, respectively. In the 240 patients without PMRT (group 2), IBR with expander was performed in 81 patients, with implant – in 159 cases. Pooled analysis revealed that overall rate of complications in the PMRT group was 33.8 % (in 95 of 281 patients), in non-irradiation patients – 22.9 % (in 55 of 240 patients), p 0.01. In group 1, RF were recorded in 67 (23.8 %) patients, in group 2 – in 44 (18.3 %) patients, p 0.05. CC in group 1 were detected in 28 (10 %) patients, in group 2 in 11 (4.6 %) patients, p 0.05. In patients with permanent implants RF were detected in 21 (14.6 %) of irradiation patients and in 22 (13.8 %) non-irradiation patients (p 0.2). On the contrary, CC were mentioned in 22 (16.1 %) of irradiated patient and in 8 (5 %) patients that didn’t receive PMRT, p 0.005. After reconstruction with expander RF were diagnosed in 46 (31.9 %) patients after PMRT and in 22 (27.2 %) non-irradiation patients, p 0.2. CC were observed in 6 (4.2 %) patients from PMRT group and in 3 (3.7 %) patients treated without PMRT, p 0.2.Conclusion. PMRT in patients after IBR with simultaneous installation of a permanent implant is characterized by a decrease in the incidence of RF, but an increase in the incidence of CC.

29 December 2018 in Pediatric Traumatology, Orthopaedics and Reconstructive Surgery
Verified
Journal Article
Open access
PDF file
GUGleb E. Ulrikh
Gleb E. Ulrikh
DZDmitri V. Zabolotskii
Dmitri V. Zabolotskii
YAYuri S. Aleksandrovich
Yuri S. Aleksandrovich
VKViktor A. Koryachkin
Viktor A. Koryachkin
SNSevir N. Nezabudkin
Sevir N. Nezabudkin
УГУльрих Дарья Глебовна
Ульрих Дарья Глебовна
Levobupivacaine is an amide anesthetic, levorotatory isomer of bupivacaine. This literature review aimed to present the possibilities of levobupivacaine in the implementation of blockades for anesthesia in traumatology and orthopedics in children. Levobupivacaine is widely used for analgesia for orthopedic interventions in adults and has become an alternative to the less safe bupivacaine. The actions of levobupivacaine, bupivacaine, and ropivacaine in the implementation of neuroaxial and peripheral blockades, and the infiltration of postoperative wounds in children were compared in the present study. Levobupivacaine has been confirmed to be safe compared with bupivacaine in pediatric patients. Studies in children of different ages comparing levobupivacaine and ropivacaine, used for anesthesia in traumatology and orthopedics, indicate the same or greater analgesic potential of levobupivacaine, with a similar level of safety. Compared with ropivacaine, levobupivacaine provides comparable pain relief at lower concentrations. The presented clinical data of levobupivacaine use in children allow the expansion of the indications for anesthesia in orthopedics and traumatology. Clinical research should be continued to compare the effectiveness of different concentrations of levobupivacaine and ropivacaine in larger groups of pediatric patients. Relevant papers were obtained by searching PubMed and Scopus databases.

18 September 2024 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
ZBZh. V. Bryantseva
Zh. V. Bryantseva
IAI. A. Akulova
I. A. Akulova
TYT. S. Yaganova
T. S. Yaganova
DUD. G. Ulrikh
D. G. Ulrikh
TTT. T. Tabagua
T. T. Tabagua
SNS. N. Novikov
S. N. Novikov
Purpose: To compare dosimetric plans obtained in patients with breast cancer (BC) that underwent accelerated partial breast irradiation (APBI) by conformal external beam radiotherapy (EBRT) or interstitial high dose rate brachytherapy (HDRB).Material and methods: From 2017 to 2022 APBI was performed in 210 patients with stage I–II BC (рТ1N0M0–pT2N0M0). APBI was delivered to the tumor bed: in 99 cases — by EBRT, in another 111 patients — by HDRB. Leſt breast was irradiated in 101 women: in 51 women using HDRB, in 50 patients — by EBRT. Following dosimetric parameters were used for comparison of the dosimetric plans: Dmax – maximum dose in the organ at risk; Dmed – mean dose in the organ at risk (heart, leſt main coronary artery and its descending branch, ipsilateral lung, breast, skin and subcutaneous tissues).Results: When the tumor bed was irradiated by HDRB, in comparison with EBRT, Dmax for the skin and subcutaneous tissue decreases from 98.4 % to 68.7 %, р < 0.002. The use of HDRB made it possible to reduce the radiation load on the ipsilateral lung: Dmax decreased from 71.9 % to 42.7 % , р < 0.002; Dmed was 5.5 % for HDRB and 2.9 % for EBRT, р > 0.05. On the contrary EBRT associated with higher dose to the breast Dmed breast — 46 % in comparison with HDRB Dmed breast — 16.5 % , р < 0.002. Dose to the heart was higher with HDBT Dmax heart — 20.2 %, Dmed heart was 4.9 % than with EBRT Dmax heart — 14.4 %, Dmed heart — 0.8 %. Dose to the left coronary artery with HDRB Dmax — 6.5 % , Dmed — 3.9 % was higher than with EBRT Dmax — 3.3 % , Dmed — 1.3 % . Dose to the descending branch of the left coronary artery was higher with HDRB Dmax — 12.6 % , Dmed — 9.3 % than with EBRT Dmax — 8.9 % and Dmed — 3.4 % . But this differences were non-significant (р > 0.05).Conclusions. APBI by HDRB associated by significant reduction of the radiation dose to the ipsilateral breast lung, breast, skin and subcutaneous tissues.

3 August 2025 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
DUD. G. Ulrikh
D. G. Ulrikh
ПКП. В. Криворотько
П. В. Криворотько
EZE. K. Zhiltsova
E. K. Zhiltsova
YBYa. I. Bondarchuk
Ya. I. Bondarchuk
ASA. V. Solomakhina
A. V. Solomakhina
VSV. F. Semiglazov
V. F. Semiglazov
Background. Malignant neoplasms occur in 0.05–0.1 % of all pregnancies, breast cancer (BC) is the most common malignant neoplasm associated with pregnancy. The prognosis of this pathology remains a subject of debate due to conflicting research findings and requires a multidisciplinary approach to minimize risks for both mother and fetus. The prognosis of this pathology remains a subject of debate due to conflicting research findings and requires a multidisciplinary approach to minimize risks for both mother and fetus.Aim. Identification of problems in clinical and morphological diagnostics of pregnancy-associated BC to improve treatment outcomes.Materials and methods. This study included 35 patients over the age of 18 years with a diagnosis of breast cancer during pregnancy, who received treatment at the N.N. Petrov National Medical Research Oncology Center and the V.A. Almazov National Medical Research Center from May 2017 to March 2024.Results. The average age of patients was 35.34 ± 3.57 years. The diagnosis was established on average at 23 weeks of pregnancy, at stages II–III of the disease. 21 patients (60 %) were estrogen-receptor- and progesterone-receptornegative by the immunohistochemical subtype. Genetic mutations were detected in 30.3 % of cases. Pregnancy was terminated in 3 (8.8 %) patients. Systemic therapy during pregnancy was performed in 18 (51.4 %) patients, surgery – in 3 (8.6 %) patients, and 11 (31.4 %) women refused treatment during pregnancy and started it only after delivery. Progression of BC was detected in 8 (22.9 %) of cases. Locoregional recurrence was diagnosed in 1 (2.9 %) patient.Conclusion. The complexity of treatment and the growth of the population of patients diagnosed with pregnancyassociated BC confirm the need for analysis of individual cases, multicenter studies, and the creation of a common registry to determine clear algorithms for diagnosis and management of this pathology. For timely diagnosis of BC during pregnancy, it is necessary to conduct examinations of the mammary glands (ultrasound diagnostics) in early stages of women over 30 years of age. It is necessary to further study the division of the concepts of diagnosis of BC during pregnancy and BC during lactation (for at least 3 years after delivery) for a more accurate assessment of the prognosis of the disease and optimization of recommendations for the management of these patients.

8 May 2025 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
NBN. B. Bekkeldieva
N. B. Bekkeldieva
VSV. F. Semiglazov
V. F. Semiglazov
ПКП. В. Криворотько
П. В. Криворотько
VMV. V. Mortada
V. V. Mortada
AKA. V. Komyahov
A. V. Komyahov
TST. Yu. Semiglazova
T. Yu. Semiglazova
Introduction. Breast cancer, which occurs in young women, is more often classified as a biologically aggressive subtype (HER2+ and triple negative) compared with postmenopausal patients. At the same time, it is important to know whether age, in itself, determines a less favorable outcome of the disease in young patients.Aim. To evaluate overall and recurrence-free survival rates in premenopausal and postmenopausal patients who underwent various levels of surgery and received neoadjuvant and adjuvant systemic therapy.Materials and methods. Of the 3,450 analyzed patients, the final analysis included 265 patients with breast cancer (clinical stage T1–3N0–1M0) who received treatment between 2011 and 2019, who were divided into 2 groups depending on age category, biological tumor subtype, types of neoadjuvant and adjuvant treatment.Results. Of 265 included patients, 162 (61.1 %) were premenopausal women, 103 (38.9 %) were postmenopausal women. The median follow-up was 5 years. The 5-year overall survival was 96.8 % (95 % confidence interval (CI) 92.6–98.7) in premenopausal patients and 95.1 % (95 % CI 88.5–97.9) in postmenopausal patients. The differences in overall survival estimated using the likelihood ratio test were not statistically significant (p = 0.927). The 5-year recurrencefree survival rate was 77.6 % (95 % CI 70.3–83.3) in premenopausal patients and 84.2 % (95 % CI 75.6–90.0) in postmenopausal patients. The differences in disease-free survival estimated using the likelihood ratio test were not statistically significant (p = 0.253).Conclusion. When comparing patients with early breast cancer, overall and relapse-free survival did not depend on menopausal status. It is necessary to conduct randomized trials to determine the effectiveness of drug therapy.